Bumper Offer - Urjas oil Just @ Rs. 1 X
Zohri 500 Tablet is a commercial drug that is prescribed in the form of Tablet. Primarily, it is used for the treatment of Ear Infection, Tonsillitis, Pneumonia. Secondary and off-label uses of Zohri 500 Tablet have also been mentioned below.
Medical history of the patient along with age and gender determines the dosage of Zohri 500 Tablet. The condition it has been prescribed for, and the route of administration also determine the right dosage. Detailed information has been provided in the dosage section.
The side effects typically associated with Zohri 500 Tablet include Nausea or vomiting, Diarrhoea, Headache. Apart from the aforementioned side effects, Zohri 500 Tablet can also lead to other problems, which have been listed below. Such side effects of Zohri 500 Tablet normally do not last long and go away once the treatment is completed. Please speak with your doctor if these side effects worsen or persist for a longer duration.
In addition, Zohri 500 Tablet's effect is Safe during pregnancy and Safe for lactating mothers. It is important to know if Zohri 500 Tablet has any effect on the kidney, liver and heart. Information on such adverse effects, if any, has been given in the Zohri 500 Tablet related warnings section.
Other contraindications of Zohri 500 Tablet have been discussed in the sections ahead.
Besides this, Zohri 500 Tablet may also have severe interaction with some medicines. Refer to the list below for further details.
Along with the above-mentioned precautions, remember that taking Zohri 500 Tablet is considered safe while driving, and is addictive.
Zohri 500 Tablet is used to treat the following -
Main Benefits
Other Benefits
This is the usual dosage recommended in most common treatment cases. Please remember that every patient and their case is different, so the dosage can be different based on the disease, route of administration, patient's age and medical history.
Find the right dosage based on disease and age
| Age Group | Dosage |
| Adult |
|
| Geriatric |
|
| 13 - 18 years (Adolescent) |
|
| 2 - 12 years (Child) |
|
| Adult(Female) |
|
| Adult(Male) |
|
Based on research, the following side effects have been observed when Zohri 500 Tablet is used -
Severe
Moderate
Mild
Common
Is the use of Zohri 500 Tablet safe for pregnant women?
Zohri is safe to take during pregnancy.
Is the use of Zohri 500 Tablet safe during breastfeeding?
Zohri is completely safe for breastfeeding women.
What is the effect of Zohri 500 Tablet on the Kidneys?
Zohri has very mild side effects on the kidneys.
What is the effect of Zohri 500 Tablet on the Liver?
Zohri is rarely harmful for the liver.
What is the effect of Zohri 500 Tablet on the Heart?
Zohri has very mild side effects on the heart.
Zohri 500 Tablet should not be taken with following medicines due to severe side effects it may cause to patients -
Life Threatening
Severe
Moderate
If you are suffering from any of the following diseases, you should not take Zohri 500 Tablet unless your doctor advises you to do so -
Is this Zohri 500 Tablet habit forming or addictive?
Zohri 500 Tablet does not cause addiction.
Is it safe to drive or operate heavy machinery when consuming?
Yes, you can operate a vehicle or heavy machinery after taking Zohri 500 Tablet since it does not cause drowsiness.
Is it safe?
Zohri 500 Tablet should be used only after doctor's advice.
Is it able to treat mental disorders?
Zohri 500 Tablet is unable to treat or cure mental disorders.
Interaction between Food and Zohri 500 Tablet
Taking Zohri 500 Tablet with food does not harm your health.
Interaction between Alcohol and Zohri 500 Tablet
Due to lack of research, there is no information about the side effects of taking Zohri 500 Tablet with alcohol.
This medicine data has been created by -
B.Pharma, Pharmacy
7 Years of Experience
References
US Food and Drug Administration (FDA) [Internet]. Maryland. USA; Package leaflet information for the user; Zithromax (azithromycin)
KD Tripathi. [link]. Seventh Edition. New Delhi, India: Jaypee Brothers Medical Publishers; 2013: Page No 754